Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Engineered Virus Designed to Fight Triple-Negative Breast Cancer

By BiotechDaily International staff writers
Posted on 11 Feb 2014
Image: Breast cancer cell. Triple-negative breast cancer is an aggressive disease with few therapeutic options. Patients with such tumors can be treated only with chemotherapy (Photo courtesy of the National Cancer Institute).
Image: Breast cancer cell. Triple-negative breast cancer is an aggressive disease with few therapeutic options. Patients with such tumors can be treated only with chemotherapy (Photo courtesy of the National Cancer Institute).
Scientists have found a possible cure for one of the most deadly, aggressive, and least treatable forms of breast cancer called triple-negative breast cancer (TNBC). In laboratory research involving human cancer cells, scientists exploited a virus comparable to the one that helped eradicate smallpox to persuade cancer cells to generate a protein that makes them disposed to radioactive iodine.

The new findings were published in the February 2014 issue of Federation of American Societies for Experimental Biology’s the FASEB Journal. “We hope that the recent developments in genetic engineering, virology, and targeted radiotherapy will soon translate into an entire class of innovative oncolytic virotherapies for the treatment of deadly cancers,” said Yuman Fong, MD, a researcher involved in the work from the department of surgery at Memorial Sloan-Kettering Cancer Center (New York, NY, USA).

In the study, Dr. Fong and colleagues effectively infected and destroyed TNBC cells using a Vaccinia virus. Furthermore, the researchers were also able to utilize the virus to cause infected cancer cells produce a cell surface protein called hNIS (human Na+/I- symporter) that typically is used to concentrate iodine in thyroid cells. Expressed in thyroid cancer, the hNIS protein is why most thyroid cancers can be cured or successfully treated with a small dose of radioactive iodine, killing thyroid cancer cells expressing hNIS in the process. Equipped with the ability to compel TNBC cells to produce this protein, researchers now have a way to deliver anticancer treatments to this lethal and resistant form of cancer.

“This is an important and significant discovery that basically combines proven cures for two other diseases,” said Gerald Weissmann, MD, editor-in-chief of the FASEB Journal. “Even more exciting is that the effects of this virus and radioactive iodine are well known in people, hopefully reducing the amount of time it will take for it to reach the clinic.”

Related Links:

Memorial Sloan-Kettering Cancer Center



Channels

Genomics/Proteomics

view channel
Image: Pulsed near infrared light (shown in red) is shone onto a tumor (shown in white) that is encased in blood vessels. The tumor is imaged by photoacoustic tomography via the ultrasound emission (shown in blue) from the gold nanotubes (Photo courtesy of Jing Claussen (iThera Medical, Germany)).

Gold Nanotubes Are Novel Agents for Cancer Diagnosis and Treatment

Cancer researchers have produced a highly defined class of gold nanotubes that are suitable for use in animals as in vivo imaging nanoprobes, photothermal conversion agents, and drug delivery vehicles.... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.